Loading…
EnSilica was awarded a fully funded three-month feasibility study by a U.S. healthcare technology company to develop a wireless biosensing and therapeutic controller ASIC, valued at about US$200,000.
EnSilica secured a design implementation and manufacturing contract with a UK life-sciences technology company for a next-generation chip, with initial value of about US$1.6 million and revenue starting in FY 2027.